21 CFR Part 820 (QMSR) Final Rule 89 FR 7496 published 31 January 2024 + applies from 2 February 2026. The QMSR replaces the prior Quality System Regulation (QSR) which had been in effect since 1996. Key transitions: (a) HARMONISATION with ISO 13485:2016 + incorporation by reference; (b) reduced FDA-specific regulatory text - QSR §820.20-820.250 replaced with QMSR §820.10/15/35/45 + the ISO 13485 substance; (c) FDA-specific additions retained where US-specific requirements differ from ISO (UDI + MDR + Part 11 audit trail + §820.45 device labelling). FUTURE EVOLUTION: (a) FDA continued harmonisation with international standards including IEC 62304 medical device software + ISO 14971 risk management + ISO 14155 clinical investigation + IEC 62366-1 usability; (b) cybersecurity integration via Cures Act 524B + 2024 FDA Premarket Cybersecurity Guidance + SBOM expectations; (c) AI/ML integration - FDA 2024 + 2025 AI/ML Action Plan + the Predetermined Change Control Plan (PCCP) for AI/ML-enabled medical devices; (d) Quality Management Maturity (QMM) framework - voluntary pilot programme integrating MAPP 5240.5 + extending to manufacturing maturity assessment. ENFORCEMENT: FDA Center for Devices and Radiological Health (CDRH) + ORA + Compliance Officers will inspect QMSR + the FDA has clarified that the QMSR transition does not require re-certification + existing QSR-compliant systems are evaluated against QMSR during routine inspections from 2 February 2026 onwards.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.